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Objectives: This study examined the association of anatomic and temporal characteristics of graft-threatening lesions with
the efficacy of percutaneous and open graft revision for failing infrainguinal vein grafts.
Methods: Consecutive open and endovascular revisions for graft threatening lesions were reviewed. We evaluated graft
durability and individual target lesion response to open and endovascular treatment to determine characteristics that may
influence outcomes. Treatment failure was defined as target lesion restenosis or graft occlusion.
Results: Eighty-four (58 endovascular, 26 open) infrainguinal vein graft revisions were performed in 67 failing,
nonthrombosed infrainguinal vein grafts. Primary assisted graft patency at 5 years was 63% (95% confidence interval [CI],
46% to 77%). Follow-up was 29.5  19.2 months. Grafts treated for early lesions (<6 months) failed (occlusion or need
for additional interventions) more frequently than those with late occurring lesions (P  .03). Overall target lesion
revascularization patency was 45% (95% CI, 32% to 58%) at 3 years. Average time to target lesion revascularization failure
was 7.5 months, with no significant difference noted between endovascular and open treatment groups. Overall target
lesion revascularization patency at 3 years was also not significantly different between open and endovascular groups at
54% (95%CI, 30% to 73%) vs 41% (95%CI, 25% to 56%; P .15).When divided by early and late-occurring target lesions,
endovascular treatment of early lesions was associated with inferior patency compared with open procedures; no
difference in patency was seen between treatment groups for late lesions. When divided by target lesion location
(anastomotic vs mid-graft), treatment for both proximal and distal anastomotic target lesion was associated with inferior
patency compared with mid-graft revision at 32% (95% CI, 17% to 47%) vs 62% (95% CI, 37% to 87%) at 3 years (P .03).
In addition, although results of anastomotic target lesion treatment significantly favored open repair, even open repair of
anastomotic target lesions was associated with a<50% patency rate at 3 years. In contrast, mid-graft target lesions treated
with open revisions were uniformly successful compared with a 54% patency at 3 years with endovascular treatment (P
.24). Short lesions (<2 cm) fared equally well with either endovascular or open treatment. Univariate analysis noted only
anastomotic treatment was associated with significantly increased odds of failure.
Conclusion:Grafts that develop early lesions fare poorly regardless of treatment modality. Lesions involving anastomoses
of failing grafts are better treated with open revision, but patency after treatment of such lesions is still worse than
treatment of mid-graft lesions. In contrast, the method of treatment does not influence outcome after treatment of
mid-graft target lesions. Thus, endovascular therapy should be reserved for focal, late-appearing lesions involving the
mid-graft. ( J Vasc Surg 2007;46:1167-72.)Determining the utility of any treatment for failing
grafts is made difficult by the variety of treatment options,
the frequent multiplicity of lesions, and specific lesion
characteristics, including length, location, and temporal
development after graft implantation. We hypothesize that
graft-threatening lesions have specific characteristics that
affect the efficacy of percutaneous and open graft revision
for failing infrainguinal vein grafts and propose a rational
treatment regime for preservation of graft patency.
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All consecutive open and endovascular revisions for
graft-threatening lesions performed between January
2000 and August 2006 in autogenous infrainguinal by-
pass grafts were reviewed. The study was approved by the
Institutional Review Board at the University of Texas
Health Science Center at San Antonio. Only repairs of
lesions considered part of the graft were included, with
deliberate exclusion of any repairs for native inflow or
outflow arterial lesions.
Failing grafts were identified through a routine graft
surveillance protocol using duplex ultrasound imaging in a
single-center noninvasive vascular laboratory accredited by
the Intersocietal Commission for the Accreditation of Vas-
cular Laboratories. Duplex diagnostic criteria for lesions
requiring interventions were used from previously de-
scribed parameters.1,2 Lesions with peak systolic velocity
300 cm/s, mid-graft velocities 45 cm/s, and velocity
ratios 3.5 were considered critical in nature, prompting
revision. Methods of repair were not randomized and var-
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interventionalist.
Graft-specific data collection. Patient characteristics,
demographics, and cardiovascular risk factors were re-
corded. In addition, specific characteristics related to the
original graft procedure were delineated, including opera-
tive indications, conduit type and configuration, inflow and
outflow source, and duplex ultrasound scan results that
detected the failing grafts. The number of lesions per graft
and time to treatment of the first lesion were recorded.
Grafts had to be patent at the time of revision, and grafts
subjected to thrombolytic therapy or thrombectomy before
revision were not included. With the full understanding
that all the grafts studied had lost primary patency, reporting
standards established by the Society for Vascular Surgery/
International Society for Cardiovascular Surgery were used.
Graft survival was calculated from the time of the original
procedure. Freedom from all-cause graft failure inclusive of
lesion recurrence and graft occlusion defined primary pa-
tency. Freedom from graft occlusion, regardless of the need
for additional intervention to maintain patency, was de-
fined as primary assisted patency.
Target lesion-specific data collection. Locations of
lesions were classified in two main groups: juxtaanasto-
motic (2 cm of an anastomosis), or intrinsic vein graft
(mid-graft), arbitrarily defined as the area between the 2 cm
range of either anastomosis. In addition, data specific to the
target lesions were collected, including lesion length (short,
2 cm; long, 2 cm) and temporal development after
original graft implantation (early, 6 months; late, 6
months). The revision method was recorded per target
lesion, defined as target lesion revascularization (TLR), and
was broadly categorized into open surgical and endovascu-
lar techniques, Target lesion end points were based on the
initial method of treatment per target lesion.
TLR failure occurred if (1) significant target lesion
restenosis occurred, (2) the initial treatment failed (intent-
to-treat), or (3) the graft occluded, regardless of the pre-
sumed culprit lesion or cause. Therefore TLR primary
patency was defined by the combined end point of freedom
from reintervention after target lesion revascularization and
freedom from graft occlusion. Significant restenosis was
defined by the same diagnostic duplex criteria for the
primary graft-threatening lesion as detailed. Duration of
TLR patency was recorded from the date of the first TLR
(t 0) to the date of failure (t date of event) and should
not be confused with graft-specific survival end points,
which begin with original graft implantation.
Statistical analysis. Statistical analyses were per-
formed using SAS 9.1 software (SAS Inc, Cary, NC).
Continuous variables were expressed as mean  standard
deviation and categoric data as percentages. Analysis of
binary outcomes and categoric variables was performed
using the Fisher exact test. Logistic regression was used to
calculate odds ratios) with 95% confidence intervals (CI).
Continuous variables were compared with the two-sampled
t test with equal variances.Survival data, including primary graft patency, assisted
primary graft patency, and TLR primary patency, were
determined using Kaplan-Meier life table analysis. Survival
results were compared with the log-rank test for equality of
survival functions. A value of P  .05 was considered
significant for all analyses. However, when two survival
probabilities at specific time points were compared, the
Z test with Bonferroni correction was used to determine
significance to ensure that the chance of false interference
was at most 5%.
RESULTS
During the study period, 64 patients (51 men, 13
women; mean age, 63  9.9 years) with 67 lower
extremity autogenous infrainguinal bypasses underwent
revision for graft threatening lesions. Indications and
operative details for the original bypass procedures, in-
cluding graft configuration, type of conduit, and proxi-
mal and distal anastomotic levels of the original lower
extremity bypasses, are summarized in Table I. Preinter-
vention data from duplex imaging was available for 63
grafts (97%). Of those grafts, 35 (56%) had low mid-graft
velocities (45 cm/s) with or without discrete stenoses.
The remaining 28 grafts had discrete stenoses without
associated low mid-graft velocities.
The initial intervention for graft-threatening lesions
was performed a mean of 12 12months after the original
procedure. Thirty-three grafts (49.3%) were treated for
index graft lesions that developed6 months after original
graft procedure, and the other 34 grafts (50.7%) developed
lesions 11 months after original bypass. Multiple lesions
developed in 18 of 67 grafts (26.9%), and 84 lesions were
repaired. Twenty-seven of the repaired lesions (32%) oc-
curred in the main graft body, and 57 (68%) occurred at an
anastomosis: 38 (67%) were at the proximal anastomosis
and 19 (33%) at a distal anastomosis. Table II summarizes
Table I. Original procedure characteristics
Characteristics No. %
Indication
Claudication 10 15
Limb threat 57 85
Inflow source
Femoral artery
Common 42 63
Deep 4 6
Superficial 16 24
Popliteal artery 5 7
Conduit
Reversed 37 55
Nonreversed 18 27
Alternative 12 18
Outflow level
Popliteal artery
Above knee 11 16.4
Below knee 21 31.3
Tibial artery 31 46.3
Pedal artery 4 6.0the primary TLR methods.
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quency to proximal anastomotic (34.5%), mid-graft
(34.5%), and distal anastomotic lesions (31%) compared
with an uneven distribution in the open group of prox-
imal anastomotic (69.2%), mid-graft (26.9%), and distal
anastomotic (3.8%; P  .003) repairs. Complications
occurred in 13 (15%) primary TLR procedures (12 en-
dovascular, 1 open; Table III).
Graft-specific results. With a mean follow-up of
29.5 19.2 months, 5-year primary assisted graft patency
(freedom from graft occlusion) was 63%  8.0% (95% CI,
46% to 77%; Fig 1). Primary patency at 5-years (freedom
from all-cause failures) was 29%  7.4% (95% CI, 16% to
44%; Fig 2). Primary assisted graft patency was not influ-
enced by age, gender, or traditional atherosclerotic risk
factors, nor by vein graft configuration, anastomotic loca-
tion, or operative indication. Furthermore, time to onset of
the index graft lesion, multiplicity of lesions, initial method
of treatment for the first TLR (open vs endovascular), need
for additional second TLR procedures for recurrent lesions
involving the index site, and need for additional interven-
tions for other lesions outside the index lesion did not have
any significant influence on overall graft survival.
A trend was noted toward worse patency among grafts
that developed early lesions (log rank, P  .06); and,
separated by specific time intervals, grafts with early lesions
had significantly worse patency at 12 and 24months of 71%
(95% CI, 51% to 84%) and 65% (95% CI, 42% to 80%)
compared with grafts with late-appearing lesions at 100%
Table II. Characteristics of primary target lesion
revascularization methods
Primary TLR N %
Open surgical 26 31
Vein patch angioplasty 19
Interposition graft 7
Endovascular 58 69
Conventional PTA 48
Cutting balloon PTA 10
Total 84 100
TLR, Target lesion revascularization; PTA, percutaneous transluminal an-
gioplasty.
Table III. Complications by procedure type
Complication No.
Open procedures
Infected lymphocele 1
Endovascular procedures
Residual stenoses 4
Distal thromboembolism 2
Access site
False aneurysm 3
Infection 2
Hematoma 1
Total 13and 90% (95% CI, 72% to 97%; P  0.001 and P  .026,respectively). However, these differences in overall pri-
mary assisted graft patency were lost during the remain-
der of follow-up, with no difference seen between groups
at 48 months: early lesion grafts were at 65% (95% CI,
42% to 80%) vs late lesion grafts at 75% (95% CI, 52% to
88%; P  .45).
Results for primary patency (freedom from all cause
failure) were similar to primary assisted patency results, and
only the development of early lesions significantly influ-
enced the primary patency of a graft (P  .03). Finally,
grafts with low mid-graft velocities (45 cm/s) had signif-
icantly worse primary patency compared with grafts with
normal mid-graft velocities and discrete stenoses (P 
.039). However, these findings did not translate to primary
assisted patency results, where no differences in rates of
Fig 1. Overall graft survival expressed as primary assisted patency,
which represents freedom from graft thrombosis regardless of
additional revision. CL, Confidence limits.
Fig 2. Overall graft survival expressed as primary patency. This
represents freedom from all-cause failures, including graft throm-
bosis, target lesion recurrence, and intervention for additional
graft-threatening lesions. CL, Confidence limits.occlusion were noted between the two groups.
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TLR primary patency was 45.4% (95% CI, 32% to 58%; Fig 3),
and the average time to TLR failure was 7.5 8.4 months.
When grouped by specific method of TLR (patch, interpo-
sition graft, or balloon angioplasty), no differences were
seen in overall TLR primary patency (P  .12). When
grouped according to TLR strategy (open vs endovascu-
lar), TLR primary patency was also not different over 3
years if a lesion was treated with open surgery or endovas-
cular intervention: 52% (95% CI, 28% to 71%) vs 31% (95%
CI, –12% to 51%; P  .17), respectively.
Additional secondary interventions were required to
salvage primary TLR failures in 28 lesions (35%): 22 (73%)
required a single secondary intervention, six (20%) required
two additional procedures, and two (7%) required three
repeat interventions. However, the mean number of addi-
tional primary target lesion reinterventions did not differ
between lesions treated initially with endovascular therapy
(1.3  0.5) compared with lesions initially treated with
surgical therapy (1.8  0.8.). In contrast, TLR recurrence
was significantly higher among patients who had complica-
tions compared with uncomplicated procedures (P 
.013).
Treatment of shorter lesions (2-cm long) was associ-
ated with significantly better patency than treatment of
longer lesions (Table V), and treatment of longer lesions
was associated with uniformly poor primary patency regard-
less of treatment modality (Table IV). Although no differ-
ence was seen in treatment durability for early (6months)
lesions compared with lesions developing 6 months (Ta-
ble V), early lesions treated with endovascular therapy also
had inferior patency compared with open surgery at 3 years
(Table IV). In contrast, this difference was not seen with
treatment of late occurring lesions, with both treatment
modalities being associated with similar 3-year patency
Fig 3. Overall target lesion revascularization primary patency.
This represents survival data specific to a particular target lesion
intervention rather than overall graft survival. CL, Confidence
limits.rates.The comparison between anastomotic vs mid-graft tar-
get lesion location showed that patency for any interven-
tions performed at an anastomotic site (proximal or distal)
was inferior to that of interventions performed in the
mid-graft (Table V). The 3-year patency of anastomotic
stenoses treated with open repair was also superior to
results of endovascular therapy of such lesions (Table IV).
Furthermore, mid-graft lesions treated with open revisions
were uniformly successful over 36 months compared with
54% TLR primary patency (95% CI, 28% to 74%) seen with
endovascular therapy (P .24). Finally, failure risk of TLR
was 3-fold higher in the treatment of anastomotic lesions
compared with mid-graft lesions by univariant analysis
(odds ratio, 3.3; 95% CI, 1.2 to 8.7) whereas gender, risk
factors, lesion length, lesion timing or initial TLR strategy
(open vs endovascular) were not significant.
DISCUSSION
Our overall graft survival (primary assisted patency) of
63% at 5 years is consistent with other reports,3-6 and the
only characteristic that seemed to influence late graft pa-
tency was the development of lesions 6 months after the
original bypass. This likely is a reflection of the aggressive-
ness of early occurring lesions and restenosis rates charac-
teristic of treatment of these target lesions. Mills et al2
suggested that most grafts that develop significant early
lesions requiring revision have identifiable flow distur-
bances manifesting at implantation or 3 months after
implantation.2
Therefore, it may be reasonable to assume that early
lesions are indicative of poor initial conduit, a characteristic
associated with compromised outcomes.7,8
Despite the unfavorable failure rate of maintenance
Table IV. Target lesion primary patency at 3 years by
type of repair
Lesion characteristic Open Endovascular P
Short, 2 cm 65% 35% .12
Long, 2 cm 22% 11% .01
Early, 6 mon 64% 18% .05
Late, 6 mon 43% 55% .75
Anastomotic location 46% 16% .01
Mid-graft location 100% 54% .11
NS, Not significant.
Table V. Target lesion primary patency at 3 years
Lesion characteristic Overall P
Short, 2 cm 47% .009
Long, 2 cm 13%
Early, 6 mon 34% .09
Late, 6 mon 50%
Anastomotic location 32% .03
Mid-graft location 62%
NS, Not significant.procedures performed on grafts with early lesions, overall
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for such grafts was not different compared with grafts
undergoing similar procedures for later appearing lesions.
This appears to be largely the result of aggressive interven-
tion and reintervention on culprit lesions, further validating
the need for maintenance intervention.
The response of a particular target lesion to interven-
tion is the important focus of the current study. Treatment
of shorter lesions was associated with significantly longer
patency than treatment of longer lesions. Regardless of the
modality of therapy, longer lesions were also associated
with poor overall patency. However, open surgical treat-
ment of long lesions, although ultimately resulting in fail-
ure, did take approximately 6 months longer to fail com-
pared with endovascular therapy. Despite the uniform poor
outcome for any revision of a long lesion, an open surgical
strategy therefore appears to buy more time before the next
failure event and may reduce the number of graft salvage
procedures required to maintain overall primary assisted
graft patency.
Endovascular treatment of early developing lesions has
been discouraged.3,5,9 Some postulate that the metabolic
activity of these early lesions may predispose them to more
rapid restenoses after intervention.3,5 Our study results
reaffirm these findings. Endovascular intervention was as-
sociated with worse outcomes for the treatment of early
graft-threatening lesions, and open surgical intervention
was associated with a much longer patency. This difference
did not translate to the treatment of late lesions, however.
With late lesions, there was no difference between the two
treatment modalities: both were associated with similar
failure rates. These observations indicate that equal success
can be expected in treatment of late-onset lesions with open
or endovascular methods, but greater consideration should
be given to treat early lesions with open surgical techniques.
Perhaps the most interesting finding in our study was
the effect of lesion location on revision outcomes. As noted
by others, anastomotic lesions tend to respond less favor-
ably to revision than lesions involving the main body of the
vein graft.10 In addition, although open repair of anasto-
motic lesions resulted in somewhat disappointing results,
with approximately 50% of interventions failing during
follow-up, endovascular treatment of anastomotic target
lesions was even more disappointing.
The fate of interventions at anastomotic sites was also
recently examined by Eagleton et al,10 and contrary to our
findings, they noted equivalent success rates between open
surgical and endovascular treatment of these lesions, with
56% and 51% cumulative patency at 3 years between endo-
vascular and open treatments, respectively. Despite the
modest response associated with open surgical treatment
for anastomotic lesions in our study, our endovascular
results were worse. The inclusion of prosthetic grafts in the
Eagleton et al study may explain the disparate results be-
tween our findings and their results.
Because performance of endovascular intervention ap-
plied to mid-graft lesions was better than anastomotic
lesions, the argument for a more liberal application ofpercutaneous therapy to mid-graft lesions can be made.
However, because open surgery was uniformly successful
compared with a 54% patency after endovascular interven-
tions, the use of percutaneous intervention should only be
driven by an avoidance of a difficult surgical dissection, such
as an anatomically tunneled graft in a large limb. That being
said, our data note higher complication rates associated
with percutaneous intervention compared with open inter-
vention, and these complications were not insignificant and
were associated with higher recurrence rates.
Our univariate analysis confirmed the results of the sur-
vival data in that the odds of successful primary target lesion
revascularization were influenced mainly by anastomotic le-
sion location. Lesion length, lesion timing, and method of
primary intervention were not significant contributors to the
odds of failure. Moreover, despite the variability of target
lesion behavior after intervention, it is important to remember
that most target lesion failures take the form of recurrent
lesions that can be secondarily treated before graft failure.
Although the fate of a particular target lesion may be resteno-
sis or recurrence, in the greater scheme of strategic graft
health, the number of reinterventions bore no impact on
ultimate graft survival. It can thus be concluded that persis-
tence in treatment of graft-threatening lesions will result in
durable occlusion free graft survival.
The generalizability of our findings is limited by the
retrospective nature of this study because there may be other
predictors of target lesion treatment success or failure that
were not evaluated. The relatively small numbers in certain
subgroups also make our data prone to type II error. In
addition, the small sample size limits adequate exploration of
outcomes related to the application of certain technologies
such as cutting balloons or plaque excision devices. Also, the
choice of intervention strategy was not random; thus, selec-
tion bias influenced the choice of treatment, and endovascular
therapy was likely applied to anatomic situations that were
considered more difficult to approach surgically. However,
the study does provide a unique look at primary target lesion
characteristics and behavior after different treatment strategies
as well as the global impact on themoremeaningful end point
of graft survival.
CONCLUSION
Early lesions within failing lower extremity vein grafts
appear to identify a compromised initial conduit. Such
grafts fare poorly regardless of treatment modality and
require extensive maintenance. Anastomotic lesions should
be treated with open surgical methods, but clinicians
should expect modest results. Long lesions and early lesions
should also be preferentially treated with open repair, and
endovascular therapy should be reserved for focal, late-
appearing lesions involving the mid-graft.
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DrMartin R. Back (Tampa, Fla). Duplex ultrasound surveil-
lance after infrainguinal vein bypass construction has been associ-
ated with meaningful extension of vein graft longevity by allowing
repair of stenotic lesions threatening patency. Graft revision meth-
ods have evolved over the last 10 years with increasing acceptance
of percutaneous transluminal balloon angioplasty as a durable
option. However, the optimal match of stenotic lesion type and
treatment method has not been fully determined.
Dr Hagino and his colleagues at San Antonio have dissected
their recent experience with secondary interventions for vein graft
stenoses using a rigorous statistical analysis to identify factors
prognosticating outcomes for endovascular and open techniques.
Their findings are not dissimilar with other series, including our
group’s experience reported in 1999. Early developing, defined as
occurring within 6 months of construction, and multiple lesions
shortened graft patency regardless of treatment method. Interven-
tions for anastomotic stenoses fared worse than repairs of graft
body lesions. Stenoses longer than 2 cm and mid-graft lesions
responded better to open repairs and probably accounted for a
general trend towards a shorter interval to restenosis seen after
endovascular interventions. Despite this latter trend, increased
graft occlusion was not observed after endovascular repairs owing
to the ability of serial scanning to effectively allow additional
re-interventions for restenoses.
I would like to thank the authors for providing me the
manuscript early and allowing me ample time to struggle through
the complex data set and its interpretation. I will limit my com-
ments regarding multiple problems with confusing patency defini-
tions and text clarity that will mandate extensive revision and better
explanation and illustration of their methods and results. I have
several queries.
First, for completeness, what was your graft surveillance pro-
tocol pre- and post-interventions? Was intraprocedural duplex
scanning used and/or how soon afterwards was imaging done as a
gauge of procedural (or technical) success? What was your proce-
dural end point for success after endovascular and open repairs, and
did this have any bearing on later outcomes?
Second, vein graft diameter has been acknowledged as a
prognostic factor for treatment durability after endovascular inter-
vention with smaller diameter veins (less than 3.5 mm) behaving
unfavorably. Have you recorded or could you extract graft diame-
ter information from duplex scans prior to intervention to includeLastly, procedural-related complications were not detailed in
the manuscript. Would their greater occurrence after open repairs
influence risk/benefit considerations and affect selection of the
preferred treatment method for any specific lesion characteristic?
Dr Ryan T. Hagino (San Antonio, TX). Thank you, Dr
Back for your questions and comments. I have found the often-
quoted practice of defining endovascular clinical end points in
terms of target lesion recurrence or reintervention rates unhelpful
in clinical practice, and I really felt the more useful end point was
overall graft patency, in other words, freedom from occlusion. And
so we tried to present our data using cumulative assisted patency.
In other words, we tried to distinguish between the end points of
graft occlusion (primary assisted patency) vs the need for secondary
interventions inclusive of graft occlusions (primary patency).
Regarding our graft surveillance protocol, certainly the South
Florida group has championed this, and then we have adopted
your guidelines for both revision and surveillance. In terms of
intraprocedural duplex, for all open repairs—both reinterventions
and the primary index procedure—we perform intraoperative du-
plex ultrasound. I did not include revisions that were performed at
the time of surgery.
Following endovascular procedures, we have not been as
aggressive as your group in terms of doing intraprocedural duplex
imaging. It is something I would like to adopt, but the practicali-
ties of our practice locations make intraprocedural scanning for
endoluminal interventions a little bit more difficult than for open
procedures. Therefore, we end up declaring technical success in
relationship to residual stenosis rather than hemodynamic resolu-
tion of the offending lesion as would be seen with intraoperative
duplex imaging, and I acknowledge that this leads to an inequality
between the groups.
In terms of vein graft diameter, I do recognize that as a
limitation and going back and trying to comb the data looking for
graft specific diameter in the absence of a prospective protocol was
impossible, so we were not able to follow that end point.
Regarding the procedure-related complications, certainly,
open procedures have their fair share of wound complications.
There was a significant difference in complications rates between
the endovascular and the open groups, with the endovascular
groups sustaining more complications. These complications were
not insubstantial. I can recall at least two or three interventions
where we had distal embolization and had to go after them with
thrombectomy catheters and percutaneous extraction techniques,
so it is by no means benign.
